You are here : Home > Research Entities > SHFJ > In Vivo Molecular Imaging > Research groups

Research groups

Clinical Applications

The “Clinical investigation” group consists of researchers, MDs, Pharmacists, highly involved in clinical research. Their goal is to design and test new imaging concepts for a better characterization of disease and for an enhanced understanding of the onset of disease, drug response and disease evolution over time, towards precision medicice. Their two main research areas are neurological diseases and cancer. 

Team Leader: Nicolas Tournier​​

Published on 28 November 2017

The Clinical Applications team builds upon the original molecular probes, imaging tools and methods developed by the other teams of the IMIV unit to propose, investigate and promote original clinical applications. The team is composed of physicians, radiopharmacists, pharmacologists, researchers, nurses and technicians specialized in nuclear medicine and clinical investigation. Members of the team strongly interact with some medical leaders in the neighborhood to provide new insights in the field of neuropsychiatric, cancer and pharmacology. ​

Fruitful collaborations prompt us to optimize the measurement of brain receptor occupancy and neurotransmission measurements us​ing PET. These exams are improved in terms of patient comfort, dosimetry and PET data accuracy using a simultaneous PET-MRI system. This objective is a prerequisite to correlate regional cerebral PET signal with subsequent neuronal activation measured using functional MRI. Once optimized, PET-MRI protocols are used to elucidate the pharmacology of drugs that exhibit high variability in their clinical response in patients. The team has also great experience in the early diagnosis of Alzheimer's Disease and atypical forms of the ​disease using amyloid load measurement and alternative PET procedures. ​

Cancer imaging is a key research axis of the team project. The predictive value of innovative imaging procedures and PET radiopharmaceuticals is assessed in terms of prognostic and/or therapeutic response in selected patients with cancer. In this framework, combined PET-MRI provides complementary information about perfusion, cellularity and biological activity of the tumor. Pharmacological imaging studies are performed to image the distribution of anticancer drugs in tumors and healthy tissues in order to improve the comprehension of pharmacoresistance processes in patients.


Team Leader: Nicolas Tournier, CEA

Badia Ourkia Helal, MCU-PH
Michel Bottlaender, IC CEA
Esther Calvo-Bota, MN CEA
Angèle Castilla-Lièvre, PH APHP
Francine Chassoux, PH
Serge Desarnaud, MN CEA
Philippe Gervais, IC CEA
Claire Leroy, IC CEA
Michaël Soussan, MCU-PH APHP
Christine Baron, IDE CEA
Christine Boireau-Manciot, IDE CEA
Christine Coulon, Tech CEA
Sébastien Goutal, Tech CEA
Thierry Lekieffre, Tech CEA
Sylvain Auvity, Doct
Viviane Brouilleret, PU PH